RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT
- Authors: Titova T.A1, Besova N.S1, Gorbunova V.A1, Fedenko A.A1, Malikhova O.A1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: No 7 (2018)
- Pages: 102-104
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295506
- ID: 295506
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
T. A Titova
N.N. Blokhin National Medical Research Center of OncologyMoscow
N. S Besova
N.N. Blokhin National Medical Research Center of Oncology
Email: besovans@mail.ru
PhD in Medical Sciences, Senior Researcher at the Department of Chemotherapy Moscow
V. A Gorbunova
N.N. Blokhin National Medical Research Center of OncologyMoscow
A. A Fedenko
N.N. Blokhin National Medical Research Center of OncologyMoscow
O. A Malikhova
N.N. Blokhin National Medical Research Center of OncologyMoscow
References
- https://www.cancer.org/cancer/stomach-cancer/ 4. detection-diagnosis-staging/survival-rates.html
- Wilson D., Hiller L., Geh J.I. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90.
- Fuchs C.S., Tomasek J., Yong C.J., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39. PMID: 24094768. doi: 10.1016/S0140-6736(13) 61719-5].
- Wilke H., Muro K., Van Cutsem E., et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-35. PMID: 25240821. doi: 10.1016/S1470-2045(14) 70420-6]
- Yang L., Jiang X., Yan H., et al. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. PMID: 29609559. doi: 10.1186/s12876-018-0772-4.
- Tabernero J., Yoshino T., Cohn A.L., et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508. PMID: 25877855. doi: 10.1016/S1470-2045(15)70127-0.
Supplementary files
![](/img/style/loading.gif)